MedTrace Logo

A Safety and Efficacy Trial of TTHX1114 in People With CED

NCT04812067 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2023-11-07

No results posted yet for this study

Summary

Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114

Conditions

  • Corneal Endothelial Dystrophy

Interventions

DRUG

TTHX1114

engineered FGF-1

Sponsors & Collaborators

  • Trefoil Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Tremblay · Trefoil Therapeutics.com

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2023-08-29
Completion
2023-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04812067 on ClinicalTrials.gov